Actively Recruiting
Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
Led by First Hospital of China Medical University · Updated on 2026-03-31
10
Participants Needed
1
Research Sites
91 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Palmoplantar pustulosis (PPP) is a chronic and recurrent skin disease, mainly characterized by erythema, pustules and scales on the palms and soles, often accompanied by itching and pain, which seriously affects the quality of life of patients. Currently, the treatment options for PPP are limited. Traditional therapies such as topical glucocorticoids, phototherapy and oral immunosuppressants have unsatisfactory efficacy, and long-term use may cause significant side effects. The introduction of biologics has provided a new direction for the treatment of PPP, but targeted therapy research for PPP is still scarce, and there are unmet clinical needs. The exploratory study of Xeligekimab in PPP is expected to provide a new treatment option, alleviate symptoms and improve the quality of life of patients. This study takes the domestic Xeligekimab as the research object, aiming to verify its potential in PPP and contribute to the breakthrough of domestic biologics in the field of refractory skin diseases. If the study is successful, it can provide preliminary evidence support for the addition of PPP as an indication for Xeligekimab and offer a preliminary theoretical basis for adding a new option to targeted therapy for PPP.
CONDITIONS
Official Title
Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Clinically diagnosed palmoplantar pustulosis (PPP) for at least 6 months
- Moderate to severe PPP with baseline PPPASI score 64; 12 and PPPIGA score 64; 3
- Dermatology Life Quality Index (DLQI) score 64; 10
- History of at least one local or systemic treatment for PPP that was ineffective or intolerable
- Signed informed consent form by patient or family
You will not qualify if you...
- Presence of other types of psoriasis such as pustular, erythrodermic, or punctate psoriasis
- Use of IL-17A inhibitors within the last 3 months or IL-23/TNF-B1 inhibitors within the last 4 months
- Severe comorbidities including ALT/AST levels more than 3 times the upper limit of normal or eGFR less than 30 mL/min/1.73 m
- Active infections including tuberculosis, hepatitis B, hepatitis C, HIV
- Pregnancy or lactation
- Known drug allergies
- Participation in other clinical studies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First Hospital of China Medical University
Shenyang, China
Actively Recruiting
Research Team
H
Hao Guo, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here